Emergent BioSolutions stock: a 66% sales jump and a cut forecast

Emergent’s second-quarter 2026 revenue rose 66% year over year to $234.3 million. That is the headline-sized improvement. The less comfortable companion: the company cut its 2026 revenue forecast to $645 million–$675 million from $720 million–$760 million, and reduced adjusted EBITDA guidance to $130 million–$150 million from $155 million–$175 million (Q2 2026 earnings release). The forecast revision is more useful for judging the year than annualizing one unusually strong quarter.

The composition explains the mismatch. MCM revenue climbed to $168.0 million in Q2 from $58.4 million a year earlier; smallpox products rose 150% to $101.6 million, and other products, chiefly BAT, contributed $54.1 million. Emergent attributed several increases to timing, including ACAM2000, VIGIV, TEMBEXA and BAT sales. The company also completed delivery of approximately $52.7 million of ACAM2000 and executed a $64.5 million BAT contract modification. Those are concrete commercial developments, but they do not establish that the same delivery volume recurs next quarter.

The first half was less dramatic: revenue rose 8% to $390.4 million, while adjusted EBITDA increased 18% to $132.0 million and adjusted net income fell 23% to $42.8 million. GAAP net loss was $173.4 million, including the impairment and a $20.5 million debt-extinguishment loss. Adjusted measures exclude several large charges and other items; the company itself cautions that non-GAAP measures are not substitutes for GAAP results. The gap is relevant because investors ultimately need cash available after interest, working capital and capital needs, not a reconciliation that grows longer as the business gets harder to read.

Naloxone revenue fell 22% to $52.4 million in Q2. Emergent attributed the decline mainly to lower over-the-counter NARCAN sales and unfavorable U.S. price-volume mix, partly offset by Canadian branded NARCAN and KLOXXADO sales (Q2 2026 earnings release).

The segment’s reported gross margin was $6.7 million, or 13% of revenue, down from 32% a year earlier. Its adjusted gross margin percentage was 31%, after adding back amortization and a small amount of stock-based compensation. The distance between the reported and adjusted figures matters: the business’s reported economics were substantially weaker than the presentation investors may focus on when evaluating ongoing operations.

Then came the $191.3 million non-cash impairment of the NARCAN asset group. An impairment is not an immediate cash payment, and it does not by itself prove the franchise has no future value. It does mean management’s carrying-value assumptions have been reset after commercial prospects weakened. The combination of lower sales, a 13% reported gross margin and a large write-down makes NARCAN a thesis hinge, not a side issue.

Medical countermeasures accounted for about 71.7% of Q2 revenue, calculated from MCM Products revenue of $168.0 million divided by total revenue of $234.3 million. That exposure can be valuable: Emergent’s products address public-health threats for which government stockpiles and procurement matter. But the buyer can defer or decline annual purchase options, funding can change, and orders arrive on delivery schedules. Emergent’s filing describes timing, funding and purchase-option exercise as causes of MCM revenue fluctuations (Q2 2026 Form 10-Q).

The Q2 release also reported international ACAM2000 approvals and new manufacturing partnerships. These demonstrate activity, not quantified incremental revenue. Likewise, management’s approximately $40 million annualized restructuring-savings target is a forecast, not realized savings. The company said the plan includes reducing approximately 90 roles. Whether the savings arrive quickly enough to offset a smaller revenue base remains open.

Competition varies by business. For naloxone, generic suppliers and alternative branded products compete for commercial sales. In biodefense, the buyer can use another qualified countermeasure supplier, stock existing inventory or exercise fewer options. For services, other contract manufacturers and customer-owned facilities are alternatives. It does not provide comparable financials or valuations, so these are research candidates, not evidence that EBS is cheaper or better.

At June 30, 2026, Emergent reported $139.7 million of cash and $589.7 million of debt principal. A September company announcement said it repurchased $75 million face value of notes for approximately $68 million cash. That transaction reduces the principal balance but also uses cash; it is not a clean $75 million reduction in net debt.

The company generated $22.3 million of operating cash flow in H1 2026, versus $95.2 million in H1 2025. Receivables used $107.7 million of cash, while inventory released $39.8 million. Receivables rose to $190.0 million at June 30 from $84.2 million at year-end; inventory stood at $303.6 million (Q2 2026 Form 10-Q). Procurement timing can make these balances swing, but it also means reported earnings and cash receipts need not arrive together.

These figures are simple division of the assumed enterprise value by the assumed multiple. Neither multiple is a sourced market benchmark, and the calculation does not forecast debt reduction, restructuring costs or dilution. The key question is whether Emergent can produce that level of durable FCF after interest and working-capital demands while maintaining government procurement.

A P/E multiple is not useful against a first-half GAAP loss. That arithmetic is not a normalized cash-earnings valuation: adjusted EBITDA excludes interest, taxes, depreciation and amortization, impairment and other adjustments. The stock may look inexpensive on a headline multiple, but the multiple cannot answer whether the debt can be serviced through a weak procurement period.

Emergent had 51.273 million shares outstanding as of July 30, 2026. The 2026 proxy estimated 24% total dilution from outstanding awards and a proposed share reserve on a fully diluted basis, or 21% excluding underwater options. Those are proxy estimates, not a forecast that every award will vest. The company’s 2026 forecast assumes approximately 52 million weighted-average diluted shares. They should not be treated as currently dilutive at the quoted price.

Debt covenant compliance was reported at June 30, but the term loan’s consolidated leverage limit is 5.25× and quarterly testing begins with the quarter ending September 30, 2026. The business therefore has two linked constraints: falling earnings can reduce covenant cushion, while working-capital outflows consume liquidity. A share-price recovery alone does not fix either one.

The bearish case would weaken if subsequent results show that MCM revenue and margins persist after timing-driven deliveries, government options are exercised, and cash collections catch up with receivables. The Canadian offer is not a minimum-revenue commitment, and savings remain management’s target until demonstrated.

The thesis would break more sharply if MCM procurement or funding falls far enough to push revenue below the revised $645 million low end; if NARCAN’s reported commercial gross margin stays near Q2’s 13% or deteriorates; or if cash after debt service and required working capital approaches liquidity or covenant limits. A breach of the 5.25× leverage covenant or 1.00× fixed-charge coverage covenant, a manufacturing quality interruption, material dilution, or inability to refinance the 2028 notes would also undermine the equity case. The Q2 filing lists government funding, product competition, quality and compliance, contract performance, pending investigations and debt covenants among the company’s risks (Q2 2026 Form 10-Q).